Although overall drug cost growth slowed in 2025, inflation continues to drive cost increases among Canadian benefits plan sponsors, according to a new report by Medavie Blue Cross.

It found in 2025, per-capita drug spending by Canadian plan sponsors increased by four per cent. While drug utilization increased by only 0.3 per cent, inflation increased by 3.6 per cent and continued to be the main factor driving overall trend. The combination of both factors resulted in a smaller increase than in the recent past, the report........

© Benefits Canada